Erste Asset Management GmbH Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Erste Asset Management GmbH reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.3% during the first quarter, Holdings Channel reports. The firm owned 37,033 shares of the biopharmaceutical company’s stock after selling 3,349 shares during the quarter. Erste Asset Management GmbH’s holdings in Regeneron Pharmaceuticals were worth $23,565,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 31 shares during the period. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $27,000. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.4%

Regeneron Pharmaceuticals stock opened at $571.78 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The business’s fifty day moving average is $546.30 and its 200 day moving average is $593.44. The stock has a market capitalization of $60.60 billion, a PE ratio of 14.41, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.56 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Analyst Ratings Changes

REGN has been the topic of several research reports. Morgan Stanley restated an “overweight” rating and set a $761.00 price target (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Citigroup reaffirmed a “buy” rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. The Goldman Sachs Group dropped their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Finally, Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.